Companies /Healthcare

Conduit Pharmaceuticals Inc

NASDAQ: CDT Biotechnology
$0.13
▼ $0.01 (−7.46%) today
Markets open · 10:44am ET

CDT at a Glance

Valuation
Market cap
$162,720
Profitability
EPS (TTM)
$82,945.94
Price
52-week range
$0 – $20,313
Earnings
Next report
Nov 12, 2026

Headquartered in Naples, FL Fiscal year ends December NASDAQ: CDT cdtequity.com

About CDT Equity

Conduit Pharmaceuticals Inc is a San Diego-based biopharmaceutical company focused on addressing autoimmune diseases and idiopathic male infertility. Founded in 2019, it is pioneering treatments with its leading drugs, AZD1656 and AZD5904, targeting conditions such as hashimoto’s thyroiditis, renal transplant complications, uveitis, preterm labor, and male infertility. As a subsidiary of Corvus Capital Limited, Conduit Pharmaceuticals is at the forefront of developing innovative solutions for critical, unmet medical needs.

CDT Coverage

Frequently Asked Questions

What does CDT Equity do?

Conduit Pharmaceuticals Inc is a San Diego-based biopharmaceutical company focused on addressing autoimmune diseases and idiopathic male infertility.